Microdosing Booms but Health Risks Surface: FDA Investigates Diamond Shruumz Chocolate Bar Illnesses

In recent years, the microdosing industry has experienced rapid growth, with companies seeking to transform substances like MDMA into legal medications. In 2020 alone, companies in the psychedelics industry raised an astonishing $163.6 million in investments during the first three quarters of the year. One such company is Diamond Shruumz, which markets its products as microdosing chocolate bars containing small doses of psychedelics.

However, a recent report from the FDA revealed that eight individuals in four states fell ill after consuming Diamond Shruumz chocolate bars. These symptoms included seizures, central nervous system depression, nausea, vomiting, agitation, abnormal heart rates, and hyper/hypotension. Despite Diamond Shruumz’s claims that their products do not contain any psychedelic substances and use only natural ingredients, it appears that their chocolate bars may be more dangerous than advertised.

All eight individuals who became ill sought medical care, with six requiring hospitalization. Fortunately, there were no reported deaths related to the consumption of these chocolate bars. The FDA is currently investigating the cause of these illnesses and determining the appropriate next steps. As of yet, Diamond Shruumz has not issued a statement regarding this situation in response to Business Insider’s request for comment.

Despite its potential dangers and questionable marketing practices, the microdosing industry continues to grow rapidly due to its perceived benefits for mental health and productivity. However, it remains important for consumers to be aware of potential risks associated with these products and consult with healthcare professionals before making any purchases or decisions related to microdosing or other forms of substance use.